北京大学皮肤性病学科已有百年历史，2001年由北京大学第一医院皮肤性病科牵头，联合北京大学人民医院和第三医院两家单位皮肤科共同成立了北京大学皮肤性病防治中心，其后成功入选教育部国家重点学科和卫计委国家临床重点专科。中心成立后逐渐形成了以皮肤肿瘤、免疫相关皮肤病、性病与感染性皮肤病、遗传性皮肤病为主的疑难重症皮肤病诊治特色专业，取得了一系列创新性研究成果，已成为国内领先，国际知名的医疗、教学和研究中心。

　　中心的研究领域及方向为：免疫性相关皮肤病；皮肤肿瘤；遗传性皮肤病；真菌及其他感染性疾病。

　　本团队拥有丰富的临床资源和大规模临床研究的坚实基础：日均门诊量愈2000人，年门诊患者60余万，年出院人数逾2000人；拥有全国最大的恶性黑素瘤、皮肤淋巴瘤、遗传性皮肤病数据库与生物样本库，以及最大规模的医学真菌菌种库；迄今已经与100余家医院签订合作协议并设立多级协作网。作为国家首批药物临床试验基地，曾牵头完成中国首个国际多中心药物临床试验；近10年牵头或参与国际多中心临床研究；包括国家I类创新药物的临床研发；牵头或参与疾病诊疗指南或共识的编写。探明7种遗传性皮肤病致病基因，研究出疼痛、瘙痒和银屑病治疗新靶点并进入临床试验。

　　本团队是国家重点学科、国家卫计委临床重点专科和教育部创新团队；拥有省部级重点实验室和多位“杰青”、“优青”、“新世纪人才”；还是“中华医学会”和“中国医师协会”皮肤科分会的创始单位；迄今连续5年在复旦专科排名中稳居第二位。申报团队近5年主持多项国家级课题；发表IF≥5分论文23篇，IF≥10分论文7篇，包括 NEJM , Nat Genet 等顶级杂志；荣获省部级奖励1项；获得国家发明专利4项；有多位骨干在国际国内术组织中担任重要职务，其中包括中华医学会和中国医师协会专科分会的前任主委和会长。

　　中心作为国家首批药物临床试验基地， 曾牵头完成中国首个国际多中心药物临床试验；近10年牵头或参与国际多中心临床研究9项，RCT研究39项，项目总数接近200项；牵头国家I类创新药物的全程临床研发；牵头或参与近40部指南的编写。在全国首报2种疾病，发现命名4个新病种，首次提出特应性皮炎中国诊断标准，于国内率先开展真菌诊断和耐药检测新方法及Mohs显微描记手术，探明7种遗传性皮肤病致病基因，研究出疼痛、瘙痒和银屑病治疗新靶点并进入临床试验。

　　

　　机构负责人：李若瑜教授

　　联系人：林志淼副教授

　　邮箱：zhimiaolin@bjmu.edu.cn

　　电话：010-83575810

　　地址：北京市西城区西什库大街八号

　　

　　

 

　　Dermatology and Venerology Center of Peking University

 

　　Department of Dermatology and Venerology of Peking University has a history of more than one hundred years. In 2001, the Dermatology and Venerology Center of Peking University was founded by the Department of Dermatology of Peking University First Hospital as the leader with the joint effort of Department of Dermatology of Peking University People’s Hospital and Peking University Third Hospital. This center has been selected as both the National Key Discipline of Ministry of Education and the National Key Clinical Specialty of National Health and Family Planning Commission of PRC. The characteristic specialties of severe and complex dermatoses mainly include neoplasms of the skin, immune dermatoses, sexually transmitted diseases, infectious dermatoses and genodermatoses. This Center has made a series of innovative research achievements, become one of the domestic leading medical centers and gained international prominence as a medical, research and educational center.

　　Research fields and directions:

　　（1）Immune related dermatosis

　　1) Mechanisms and treatment of autoimmune bullous diseases

　　2) New therapy for psoriasis

　　3) Standard diagnosis and treatment for atopic dermatitis

　　4) Mechanisms and treatment of chronic spontaneous urticaria

　　（2）Skin neoplasms

　　1) Standard diagnosis and treatment for malignant melanoma

　　2) Pathogenesis, molecular diagnosis and molecular mechanisms of drug therapy of skin lymphoma

　　3) Standards of surgical treatment of non-melanoma skin neoplasms

　　（3）Genodermatoses

　　1) Detection of pathogenic gene mutation in genodermatoses

　　2) Prenatal diagnosis of genodermatoses

　　3) Identified 7 new pathogenic genes of genodermatoses

　　（4）diagnosis and treatments of recalcitrant infective dermatoses e.g. mycoses.

　　1) Set up fungal culture collection and develop advanced detection methods

　　2) Set up normalized diagnosis system for fungal infection

　　3) Detection of drug resistance and its mechanisms

　　4) Research on susceptibility of fungal infection and its mechanisms

　　5) Standard diagnosis and treatment for sexual transmitted disease, and the use of ‘evaluation system for vaginalmicroecosystem’

　　6) Set up standard system for the diagnosis and treatment of infectious granuloma

 

　　Our team has abundant clinical resources and a solid foundation in large-scaled clinical research. The average outpatient-visit number is more than 2000 per day, 600,000 per year and the number of discharged patients is about 2000 per year. We have the largest domestic library of samples and clinical statistics of malignant melanoma, skin lymphoma and genodermatoses, and also the largest collection of fungal culture. Our team has signed cooperation agreement with more than 100 hospitals and set up multi-level cooperative networks. As one of the earlies clinical trials sites in our country, we have achieved the first international multicenter clinical trial in China as the leading unit, and joined in several international multicenter clinical trials during the past 10 years, including the development of National I Innovative Drugs and drafting of Guidelines. Seven pathogenic genes of genodermatoses were determined by our team and new therapeutic targets of pain, pruritus and psoriasis were found and were admitted in clinical trials.

　　Our team is the National Key Discipline of ministry of education, the National Key Clinical Specialty of National Health and Family Planning Commission of PRCand the Innovative Team of Ministry of Education, having many ministerial and provincial-level key laboratories, Outstanding Youths and Talents of the New Century. Besides, we are the founders of Chinese Society of Dermatology (CSD) and China Dermatologist Association (CDA). So far, it has been in the second place in the Specialty Ranking of Fudan Hospital for 5 years. Our team directed several national subjects, published a great many papers in the top journals of medicine, including 23 papers with an impact factor higher than 5, and 7 papers higher than 10, such as NEJM and Nat Genet . We have received 1 provincial-level awards and 4 National Invention Patents. Many core members of this team take important positions in the international and domestic academic associations, including the former executive directors of the CSD and CDA.

　　

　　As one of the earlies sites of clinical trials in our country, our team have achieved the first international multicenter clinical trial in China as the leading unit, and joined in 9 international multicenter clinical trials and 39 RCTs with a total of about 200 projects during the past 10 years. Besides, we have leaded the development of National I Innovative Drugs, and drafted 40 clinical guidelines as the leader or participant unit. Other main achievements could be summarized as follows: reported 2 kinds of diseases; discovered and nominated 4 kinds of diseases; put forward the Chinese diagnostic criteria of atopic dermatitis; developed new methods for the diagnosis of fungal disease and detection of drug resistance; firstly developed the Mohs surgery in China; discovered the pathogenic genes of seven genodermatoses; revealed new therapeutic targets of pain, pruritus and psoriasis, which were admitted in clinical trials.

　　

　　Director: Ruoyu Li, M.D., Prof.

　　Dept.Dermatology and Venerology

　　Peking University First Hospital

　　Beijing, China

　　Email: mycolab@126.com

　　Contact: Zhimiao Lin, M.D., Associate Professor

　　Email: zhimiaolin@bjmu.edu.cn

　　Office: 010-83575810

　　Address: Department of Dermatology, Peking University First Hospital, 8# Xishiku Street, Xicheng District, Beijing, 100034, P. R. China.